Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Purpose: This study investigated the feasibility of a one-on-one peer support intervention in family caregivers of newly diagnosed patients with a hematological cancer during initial treatment. Methods: The study was a one-arm feasibility study including family caregivers of newly diagnosed patients with hematological cancer (n = 26) and caregiver ambassadors who were family caregivers of previously treated patients as peer supporters (n = 17). The one-on-one peer support intervention consisted of three components: a caregiver ambassador preparatory course; 12 weeks of one-on-one peer support, and caregiver ambassador network meetings. Results: Family caregivers reported high satisfaction with the delivery and flexibility of one-on-one peer support and improved in most psychosocial outcomes over time. Telephone and text messages were the most used form of contact between the peers. Caregiver ambassadors reported high satisfaction with the preparatory course and used the available support from the network meetings. No adverse events were reported. Conclusion: One-on-one peer support provided by a caregiver ambassador is feasible and safe in family caregivers of newly diagnosed hematological cancer patients during their initial treatment. Utilizing volunteer caregiver ambassadors has the potential to be a new support model in family caregivers of hematological cancer patients across diagnostic groups within a clinical setting. Clinical trial registration number: NCT04039100, July 29, 2019.

TidsskriftSupportive Care in Cancer
Udgave nummer8
Sider (fra-til)6923-6935
Antal sider13
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We are grateful to all the family caregivers who participated in this study. A special thanks to the volunteer caregiver ambassadors who gave their time and energy and shared their own experiences to help others. Their contribution is valued. This study is part of the Models of Cancer Care Research Program at Copenhagen University Hospital – Rigshospitalet, funded by Novo Nordisk Foundation grant no. NNF16OC0022338 and the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071.

Funding Information:
This study is funded by the Danish Cancer Society grant number R210-A12866 and the Novo Nordisk Foundation grant number NNF19OC0058088.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

ID: 307328152